Vadadustat for Anemia in Chronic Kidney Disease
Primary Recommendation
Vadadustat is FDA-approved ONLY for dialysis-dependent CKD patients who have been on dialysis for at least 3 months; it should NOT be used in non-dialysis CKD patients due to increased risks of mortality, stroke, myocardial infarction, and serious organ injury. 1
Approved Indication
Vadadustat (VAFSEO) is indicated exclusively for treating anemia in adults with dialysis-dependent chronic kidney disease (DD-CKD) 1. The 2026 KDIGO guidelines position HIF-PHIs like vadadustat as alternatives when patients prefer oral agents, cannot tolerate ESAs, or lack access to refrigeration 2.
Dosing Regimen
Starting Dose
Dose Adjustments
- Titrate in 150 mg increments (150,300,450, or 600 mg daily) based on hemoglobin response 3, 1
- Maximum dose: 600 mg once daily 1
- Adjust every 4 weeks or longer to achieve target hemoglobin 1
Target Hemoglobin
Administration
- Take with or without food 1
- Can be administered 4 hours before or 2 hours after dialysis (no significant PK differences) 1
Monitoring Parameters
Before Initiation
- Hemoglobin, ferritin, transferrin saturation (TSAT)
- ALT, AST, and bilirubin (mandatory baseline) 1
- Blood pressure
- Iron parameters: Ensure ferritin ≤500 ng/mL and TSAT ≤30% per KDIGO 2
During Treatment
First 6 Months:
- Monthly ALT, AST, and bilirubin 1
- Hemoglobin every 2-4 weeks after initiation or dose adjustment 2, 1
- Blood pressure at each visit 1
After 6 Months:
- Liver enzymes as clinically indicated 1
- Hemoglobin monitoring frequency per KDIGO applies as for ESAs 2
- Iron parameters every 3 months 2
Discontinuation Criteria
- Persistent ALT or AST >3× ULN 1
- ALT/AST >3× ULN with bilirubin >2× ULN 1
- Insufficient erythropoietic response after 3-4 months 2
Absolute Contraindications
- Uncontrolled hypertension 1
- Active malignancy 2, 1
- Recent cardiovascular or vascular thrombotic event 2
- Non-dialysis-dependent CKD (safety not established; increased mortality and MACE risk observed in trials) 1
Critical Safety Warnings
Cardiovascular Risk
In the INNO2VATE trials (dialysis patients), vadadustat was non-inferior to darbepoetin alfa for MACE 3. However, in non-dialysis CKD patients (PRO2TECT trials), vadadustat increased mortality, stroke, MI, and serious acute kidney injury compared to darbepoetin alfa 3, 1.
Hepatotoxicity
- ALT/AST elevations >3× ULN occurred in 3.8% and 1.8% of patients 1
- Monthly monitoring mandatory for first 6 months 1
- Not recommended in cirrhosis or active liver disease 1
Hypertension
- Worsening hypertension: 14% (9.4 per 100 person-years) 1
- Hypertensive crisis and encephalopathy reported 1
- Monitor BP periodically and adjust antihypertensives 1
Gastrointestinal Erosion
- Gastric/esophageal erosions: 6.4% (4.0 per 100 person-years) 1
- Serious GI bleeding requiring transfusion: 3.4% 1
- Higher risk in patients with peptic ulcer history, tobacco/alcohol use, or concurrent NSAIDs 1
Seizures
When to Consider Vadadustat Over ESAs
Per KDIGO 2026 guidelines 2:
- Patient preference for oral agent (convenience, avoids injections)
- ESA intolerance (injection site reactions, allergic responses)
- No access to refrigeration (ESAs require cold storage)
- ESA hyporesponsiveness (trial of HIF-PHI can be considered)
Drug Interactions
Significant Interactions (from FDA label) 1:
- Probenecid: Increases vadadustat AUC by 65% (OATP1B1/1B3 inhibition)
- Rifampin: Decreases vadadustat AUC by 48% (UGT induction)
- Vadadustat increases rosuvastatin exposure by 71% (BCRP/OATP1B1/1B3 inhibition)
- Vadadustat increases metformin AUC by 52% (OCT2/MATE inhibition)
Clinical Implication: Dose adjustments may be needed for concomitant statins and metformin.
Iron Management
Suspend vadadustat during active infection per KDIGO 2. Maintain iron parameters:
- Ferritin <700 ng/mL and TSAT <40% (dialysis patients) 2
- Withhold iron if ferritin >700 ng/mL or TSAT ≥40% 2
Vadadustat improves iron utilization by reducing hepcidin 4, 5, potentially reducing IV iron requirements.
Special Populations
Renal Impairment
- Vadadustat clearance decreases with declining renal function 1
- Exposures in DD-CKD are approximately 2-fold higher than healthy adults 1
- No dose adjustment specified; titrate to hemoglobin response 1
Hepatic Impairment
- No dose adjustment for moderate impairment (Child-Pugh B) 1
- Unknown safety in severe impairment (Child-Pugh C) 1
- Not recommended in cirrhosis or active liver disease 1
Pregnancy/Lactation
Common Pitfalls to Avoid
- Do NOT use in non-dialysis CKD patients – this is the most critical error given increased mortality risk 1
- Do NOT skip monthly liver monitoring in first 6 months – hepatotoxicity can be serious 1
- Do NOT use with active malignancy – HIF activation may promote tumor growth 2, 1
- Do NOT target hemoglobin >11.5 g/dL – increases cardiovascular risk per KDIGO 2
- Do NOT continue if no response after 3-4 months – discontinue per KDIGO 2
Efficacy Data
In the INNO2VATE trials (3,923 dialysis patients), vadadustat was non-inferior to darbepoetin alfa 3:
- Mean hemoglobin change at weeks 24-36: vadadustat 0.19-1.26 g/dL vs. darbepoetin 0.36-1.58 g/dL
- Patients achieving target hemoglobin: 43.6-60.1% (vadadustat) vs. 50.2-60.7% (darbepoetin)
- MACE hazard ratio: 0.96 (95% CI 0.83-1.11) – demonstrating cardiovascular non-inferiority 3